This $38.8 Million Vicor Bet Is Getting Bigger Amid a 200% Stock Surge Vicor Corporation designs advanced power conversion solutions for sectors like aerospace, defense, and industrial automation.
Sportradar Stock Down 26%, but One Fund Just Disclosed a New $12.6 Million Stake Specializing in sports data and analytics, Sportradar serves betting operators, leagues, and media with real-time technology solutions.
What Investors Should Know as One Fund Sells $11 Million of Cavco Industries Stock This Arizona-based firm provides factory-built homes and modular units to residential and commercial clients across North America.
Fund Sells $23 Million in Globalstar as Stock Surges 170% in One Year Globalstar delivers satellite communications and IoT connectivity to enterprise and government clients across critical industries worldwide.
Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out This digital banking platform targets U.S. mass market consumers with mobile-first, fee-free services and strategic bank partnerships.
Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth Solaris Energy Infrastructure delivers automation and logistics solutions to U.S. oil and gas operators using proprietary technologies.
Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look Boot Barn Holdings operates over 500 stores nationwide, supplying western and workwear apparel to a diverse U.S. customer base.
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.
This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know A high-conviction fund just trimmed one of its biggest winners—here’s what long-term investors should make of the move.
Why One Small-Cap Fund Bought $11 Million in Cellebrite Stock Last Quarter A specialist small-cap fund just doubled down on a digital-intelligence company that's underperforming the broader market.
This Fund Cut $7.3 Million of Atlas Energy Stock as the Company Suspends Its Dividend to Help Fuel Growth One fund just took a step back from a struggling energy name—right as the company suspended its dividend to fund future growth.
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (
NASDAQ: LGND ) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025. This significant milestone comes on the heels of a robust third-quarter 2025 earnings report that dramatically exceeded analyst expectations,
Ligand Pharmaceuticals (NASDAQ:LGND) Surges on Strong Q3 2025 Earnings Beat and Raised Guidance Ligand (LGND) smashed Q3 2025 earnings estimates, driven by 47% royalty growth. The company also raised its full-year 2025 revenue and EPS guidance.
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance Johnson & Johnson (
NYSE: JNJ ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter for 2025. The company's performance was marked by significant growth across its Innovative Medicine and MedTech segments, showcasing the strategic success of its
Ligand Pharmaceuticals (NASDAQ:LGND) Surpasses Q2 2025 Earnings Estimates with Strong Royalty Growth Ligand Pharmaceuticals (LGND) beat Q2 2025 earnings estimates with strong royalty growth, raising full-year guidance. Stock dipped slightly pre-market but gained 16.3% over the past month.
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.
